MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
ROCKVILLE, Md., Nov. 12, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. NASDAQ:MGNX, a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended September 30, 2026, and highli…